CA2468839A1 - Methods of treating cancer using an fpt inhibitor and anti neoplastic agents - Google Patents

Methods of treating cancer using an fpt inhibitor and anti neoplastic agents Download PDF

Info

Publication number
CA2468839A1
CA2468839A1 CA002468839A CA2468839A CA2468839A1 CA 2468839 A1 CA2468839 A1 CA 2468839A1 CA 002468839 A CA002468839 A CA 002468839A CA 2468839 A CA2468839 A CA 2468839A CA 2468839 A1 CA2468839 A1 CA 2468839A1
Authority
CA
Canada
Prior art keywords
administered
amount
day
fpt inhibitor
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468839A
Other languages
English (en)
French (fr)
Inventor
David L. Cutler
Michael L. Meyers
Charles Baum
Sara L. Zaknoen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468839A1 publication Critical patent/CA2468839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002468839A 2001-11-30 2002-11-25 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents Abandoned CA2468839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334,411 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
CA2468839A1 true CA2468839A1 (en) 2003-06-12

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468839A Abandoned CA2468839A1 (en) 2001-11-30 2002-11-25 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents

Country Status (13)

Country Link
US (2) US20030185831A1 (enExample)
EP (1) EP1448268A2 (enExample)
JP (1) JP2005511663A (enExample)
CN (2) CN1617755A (enExample)
AU (1) AU2002352941A1 (enExample)
BR (1) BR0214564A (enExample)
CA (1) CA2468839A1 (enExample)
HU (1) HUP0402401A2 (enExample)
MX (1) MXPA04005207A (enExample)
NO (1) NO20042730L (enExample)
NZ (1) NZ532562A (enExample)
WO (1) WO2003047697A2 (enExample)
ZA (1) ZA200403737B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
CA2557504C (en) * 2004-02-26 2020-12-01 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
US20100069411A1 (en) * 2006-11-28 2010-03-18 Smithkline Beecham (Cork) Ltd. Cancer treatment method
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
EP4615842A1 (en) 2022-11-09 2025-09-17 Merck Patent GmbH Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PT1041985E (pt) * 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
PT1255537E (pt) * 2000-02-04 2006-09-29 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratar cancro da mama
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
MXPA03003011A (es) * 2000-10-05 2003-07-14 George Q Daley Metodos para inducir muerte de celulas cancerosas y regresion de tumores.

Also Published As

Publication number Publication date
US20030185831A1 (en) 2003-10-02
BR0214564A (pt) 2004-11-09
US20060183765A1 (en) 2006-08-17
EP1448268A2 (en) 2004-08-25
JP2005511663A (ja) 2005-04-28
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
AU2002352941A1 (en) 2003-06-17
WO2003047697A3 (en) 2003-10-30
MXPA04005207A (es) 2004-08-19
ZA200403737B (en) 2005-05-23
WO2003047697A2 (en) 2003-06-12
CN1617755A (zh) 2005-05-18
HUP0402401A2 (hu) 2005-03-29
NO20042730L (no) 2004-06-29

Similar Documents

Publication Publication Date Title
EP4506004A1 (en) Pharmaceutical composition, use thereof, and method for treating cancer
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
JP2021059564A (ja) 癌治療のための併用療法
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
KR20090040926A (ko) 암 치료용 배합 생성물
JP2003533485A5 (enExample)
JP2011522773A5 (enExample)
JP6898329B2 (ja) 併用療法
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
US20060183765A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
JP2005511663A5 (enExample)
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
WO2004032925A1 (en) Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
Mayerhofer et al. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
MX2007013830A (es) Terapia de combinacion.
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
CN120154734A (zh) 维奈克拉联合瑞戈非尼在治疗急性髓系白血病中的应用
Von Pawel Topotecan (Hycamtin®): potent cytostatic action by selective topoisomerase I inhibition

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued